GSK3B and Alzheimer disease: AstraZeneca described ATP-competitive GSK3β inhibitors such AZD1080 as orally active & brain permeable GSK-3 inhibitors that inhibited human GSK-3β in the nanomolar range, however owing to nephrotoxicity in phase 1 clinical study targeting AD, further development of this inhibitor was terminated.